Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort

This is an open-label, multicenter, two-arm Phase II clinical trial that will evaluate the impact of 2nd line chemotherapy (i.e. capecitabine) on survival in patients with non-Luminal A hormone receptor-positive (HR+) metastatic breast cancer (MBC)

Trial Details

NCT ID
NCT05693766
Phase
PHASE2
Sponsor
Sonya Reid
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Capecitabine
  • Endocrine-therapy
  • MammoPrint ® and BluePrint assays
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Memphis, Tennessee, United States|35.14953,-90.04898
  • Nashville, Tennessee, United States|36.16589,-86.78444
  • Dallas, Texas, United States|32.78306,-96.80667

Key Eligibility Criteria

  • Signed and dated written informed consent.
  • Subjects ≥ 18 years of age.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
  • Clinical stage IV invasive mammary carcinoma or unresectable locoregional recurrence of invasive mammary carcinoma that is:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →